Amgen (AMGN) Contingent consideration — Quarterly & Annual

Screener

Contingent consideration at other companies

AmgenAMGN

$116M+50.6%

Sarepta Therapeutics, Inc.SRPT

$246K-57.1%

Microchip TechnologyMCHP

$18.9M-14.9%

PTH

Pelthos TherapeuticsPTHS

-$1.2M—

CareDxCDNA

$0—

Pacira BioSciences, Inc.PCRX

$15.79M-10.1%

Other financials

Income statement

Revenue$10.1B+9.5%

Gross profit$7.2B+17.4%

Operating income$3.5B+32.3%

Net income$2.4B+65.9%

EPS (diluted)$4.37+64.9%

Balance sheet

Cash & equivalents$574.0M+5.9%

Total debt$57.3B+2.0%

Total equity$11.7B+57.4%

Total assets$95.6B+8.8%

Cash flow

Operating cash flow$4.0B+75.5%

CapEx$513.0M+39.0%

Free cash flow$3.5B+82.6%

Valuation

Market cap$220.64B+44.0%

Enterprise value$277.37B+32.8%

P/E25.2×+2.1×

P/S5.8×+1.4×

Profitability

Gross margin69.5%+5.0pp

Operating margin30%+6.5pp

Net margin23%+4.0pp

FCF margin26.7%-3.7pp

Returns & leverage

Return on equity91.5%-7.7pp

Debt / equity4.9×-2.7×

Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:OtherNonrecurringIncomeExpense.

The source filing: Amgen’s 10-Q, filed August 5, 2026. Open the filing →

Filed: Aug 4, 2026, 8:00 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000318154-26-000126

FAQ

What is Amgen's contingent consideration?: Amgen (AMGN) reported contingent consideration of $116M in Q2 2026.
What does contingent consideration mean?: Contingent consideration as reported by Amgen Inc.

Ask your AI about Amgen's contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk